Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging (CHAOSBOLD)

August 13, 2013 updated by: Assistance Publique - Hôpitaux de Paris

Central Control of Breathing in Patients With Chronic Obstructive Pulmonary Disease: Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging

Chronic obstructive pulmonary disease (COPD) is a chronicle inflammatory disease with a non reversible diminution of the airway flow. COPD is caused most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung. Worldwide, COPD ranked as the sixth leading cause of death in 1990. It is projected to be the fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and demographic changes in many countries. COPD is responsible for 16000 deaths per year in France, 100 000 hospitalizations per year and the health care expenditure of COPD in France is 3.5 billion of Euros. Classical markers of the disease severity, the forced expiratory volume in one second, poorly correlates with dyspnea and prognosis. Therefore, many studies focused on the control of breathing in an attempt to understand the pathophysiological mechanisms involved in the progression of the disease. Breathing control is enhanced in patients with COPD due to the progressive failure of respiratory muscles (airflow obstruction, static and dynamic hyperinflation, positive intrinsic end expiratory pressure), the ventilation/ perfusion ratio abnormalities leading to the loss of the gaz exchange efficiency. Inspiratory command depends on the medulla automatic pathway and the voluntary corticospinal command. Indirect method of breathing control estimation suggested in COPD patients an increased excitability of neurons involved in the voluntary diaphragm activation and a reduced cortical reserve. This may represent an increase risk factor for acute respiratory failure. Until now, no study reported the central breathing control with cerebral fMRI in COPD patients.

Study Overview

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a chronicle inflammatory disease with a non reversible diminution of the airway flow. COPD is caused most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung. Worldwide, COPD ranked as the sixth leading cause of death in 1990. It is projected to be the fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and demographic changes in many countries. COPD is responsible for 16000 deaths per year in France, 100 000 hospitalizations per year and the health care expenditure of COPD in France is 3.5 billion of Euros. Classical markers of the disease severity, the forced expiratory volume in one second, poorly correlates with dyspnea and prognosis. Therefore, many studies focused on the control of breathing in an attempt to understand the pathophysiological mechanisms involved in the progression of the disease. Breathing control is enhanced in patients with COPD due to the progressive failure of respiratory muscles (airflow obstruction, static and dynamic hyperinflation, positive intrinsic end expiratory pressure), the ventilation/ perfusion ratio abnormalities leading to the loss of the gaz exchange efficiency. Inspiratory command depends on the medulla automatic pathway and the voluntary corticospinal command. Indirect method of breathing control estimation suggested in COPD patients an increased excitability of neurons involved in the voluntary diaphragm activation and a reduced cortical reserve. This may represent an increase risk factor for acute respiratory failure. Until now, no study reported the central breathing control with cerebral fMRI in COPD patients. This pilot study also aims in estimating if the absence or diminution of the cortical reserve is a marker of disease severity. In addition correlations will be performed between activated neuronal signals with fMRI and ventilatory flow output recordings (chaotic analysis).

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75018
        • Hôpital Bichat

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

INCLUSION CRITERIA for Patient:

  • Informed patients with written consent,
  • More than eighteen years old,
  • Patients having a social insurance
  • A previous medical examination
  • Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD will be included. These patients will be clinically in a steady state situation for at least one month (no acute exacerbation). GOLD grading of COPD patients will be performed according to the American Thoracic Society.

EXCLUSION CRITERIA for patient:

  • Long-term oxygen therapy
  • Previous cerebral vascular accident
  • Central neurological disease (tumor, Parkinson, etc.)
  • Nobody benefiting from a particular protection: pregnant woman, minor person, major person under guardianship and under guardianship, the persons hospitalized without their consent and protected by the law, or the private persons of freedom.
  • Contraindication in the functional intellectual MRI:
  • Port of a biomedical device like cardiac simulator
  • Cardiac defibrillator
  • Insulin pump or neurostimulating,
  • Claustrophobia,
  • Impossibility to remain lengthened
  • Presence of cerebral vascular clips, metallic foreign body intra-ocular, not compatible cardiac valve
  • Pregnancy

INCLUSION CRITERIA for Healthy Volunteers:

  • Informed healthy volunteer with written consent,
  • More than eighteen years old,
  • Healthy volunteer having a social insurance
  • A previous medical examination
  • Non-smoker
  • Non pathology and medicinal treatment

EXCLUSION CRITERIA for healthy volunteers:

  • Nobody benefiting from a particular protection: pregnant woman, minor person, major person under guardianship and under guardianship, the persons hospitalized without their consent and protected by the law, or the private persons of freedom.
  • Contraindication in the functional intellectual MRI:
  • Port of a biomedical device like cardiac simulator
  • Cardiac defibrillator
  • Insulin pump or neurostimulating,
  • Claustrophobia,
  • Impossibility to remain lengthened
  • Presence of cerebral vascular clips, metallic foreign body intra-ocular, not compatible cardiac valve
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PATIENT
Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
the central breathing control with cerebral fMRI in COPD patients
Other Names:
  • the central breathing control with cerebral fMRI
the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
Other Names:
  • the central breathing control with cerebral fMRI
Other: Accepts Healthy Volunteers
Control arm with the same intervention
the central breathing control with cerebral fMRI in COPD patients
Other Names:
  • the central breathing control with cerebral fMRI
the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
Other Names:
  • the central breathing control with cerebral fMRI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Central ventilatory control
Time Frame: 1 month
Evaluation of the central ventilatory control at the patients COPD during the application of an inspiratory resistance.
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the neuronal activation
Time Frame: 1 month
Evaluation of the neuronal activation bulbo-pontique and corticospinal during the application of an inspiratory resistance.
1 month
Chaotic analysis
Time Frame: 1 month
The correlations will be performed between activated neuronal signals with fMRI and ventilatory flow output recordings (chaotic analysis).
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laurence MANGIN, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (Actual)

March 1, 2012

Study Completion (Actual)

March 1, 2013

Study Registration Dates

First Submitted

April 4, 2011

First Submitted That Met QC Criteria

April 6, 2011

First Posted (Estimate)

April 7, 2011

Study Record Updates

Last Update Posted (Estimate)

August 14, 2013

Last Update Submitted That Met QC Criteria

August 13, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • P100136
  • AOM10010 (Other Identifier: French Ministry)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on cerebral fMRI

Subscribe